Core Viewpoint - REGENXBIO Inc. has announced that the FDA has placed a clinical hold on its investigational gene therapies RGX-111 and RGX-121 due to a case of neoplasm identified in a participant treated with RGX-111, raising concerns about the safety of both therapies [1][2]. Group 1: Clinical Hold Details - The FDA's clinical hold on RGX-111 and RGX-121 is based on a single case of an intraventricular CNS tumor found in a five-year-old participant who received RGX-111 four years prior [1][2]. - Preliminary genetic analysis of the tumor indicated an AAV vector genome integration event linked to overexpression of the proto-oncogene PLAG1, which is associated with chromosomal rearrangements [2]. Group 2: Company Response - REGENXBIO expressed surprise at the FDA's decision to place RGX-121 on hold, emphasizing that RGX-121 has a positive safety profile based on data from over 30 patients treated [3]. - The company highlighted the urgent medical need for RGX-121 in treating MPS II, stating that delays could lead to neurodevelopmental decline in affected patients [3]. Group 3: Therapy Information - RGX-121 is a one-time gene therapy designed to deliver the iduronate-2-sulfatase (IDS) gene to the CNS, potentially providing a permanent source of the I2S protein beyond the blood-brain barrier [4]. - RGX-111 aims to deliver the alpha-L-iduronidase (IDUA) gene to the CNS, which could help prevent cognitive deficits in MPS I patients [7]. Group 4: Disease Background - MPS II, or Hunter Syndrome, is a rare disease caused by a deficiency in the lysosomal enzyme I2S, leading to the accumulation of glycosaminoglycans and resulting in dysfunction across various tissues, including the CNS [6]. - MPS I is a rare genetic disease caused by a deficiency in the enzyme IDUA, leading to similar accumulations and dysfunctions, with an estimated occurrence of 1 in 100,000 births [9].

Core Thesis - REGENXBIO Inc. presents a bullish investment opportunity due to its strong pipeline, strategic partnerships, and favorable market positioning in gene therapies [1][5]. Company Overview - REGENXBIO is a clinical-stage biotechnology company focused on gene therapies utilizing its proprietary NAV Technology platform, specifically AAV8 and AAV9 vectors [2]. - The lead program, suragene lomparvovec (sura-vec, ABBV-RGX-314), targets wet age-related macular degeneration and diabetic retinopathy, significantly reducing the need for repeated injections [2]. Clinical Programs - The company has the largest retinal gene therapy program to date, with over 1,200 patients enrolled in pivotal trials ATMOSPHERE and ASCENT [3]. - REGENXBIO is also advancing RGX-202 for Duchenne muscular dystrophy and RGX-121 for MPS II, with RGX-121 showing an 82% median reduction in a cerebrospinal fluid biomarker linked to neurodevelopmental stabilization [3]. Financial Position - As of early 2026, REGENXBIO has a solid liquidity position of approximately $302 million, supported by recent non-dilutive financings [4]. - This capital is expected to fund operations into early 2027, excluding significant milestone payments from AbbVie related to late-stage trials [4]. Market Position and Strategy - The company is strategically positioned in competitive markets favoring durable, long-acting therapies, with Phase 2 data in wet AMD showing favorable comparisons to emerging peers [4]. - AbbVie's commercial infrastructure provides a significant execution advantage for REGENXBIO [4]. Upcoming Catalysts - An FDA PDUFA date for RGX-121 is set for February 2026, with pivotal readouts for wet AMD expected in late 2026, indicating a catalyst-rich investment profile [5]. - The current valuation of REGENXBIO is seen as underappreciating the depth of its pipeline and the strength of its partnerships [5].

Summary of Regenxbio FY Conference Call (January 14, 2026) Company Overview - **Company**: Regenxbio (NasdaqGS: RGNX) - **Key Speakers**: Curran Simpson (CEO), Mitch Chan (CFO), Dr. Steve Pakola (CMO) [1] Industry and Technology - **Industry**: Gene Therapy - **Technology**: AAV (Adeno-Associated Virus) gene therapy with over 5,000 patients dosed [2][3] - **Focus**: Development of new capsids to enhance therapeutic efficacy and safety [5] Core Points and Arguments Pipeline and Product Development - **BLA Review**: The company has a Biologics License Application (BLA) under review for the Hunter program, with a PDUFA date of February 8, 2026 [8][22]. - **Late-Stage Programs**: Top-line readouts expected for two late-stage programs: Duchenne program (RGX-202) in Q2 2026 and wet AMD program (RGX-314) with AbbVie later in 2026 [4][8]. - **Duchenne Program**: Aiming to provide functional benefits to children with Duchenne muscular dystrophy, with pivotal data showing significant improvements in patient outcomes [10][11][19]. - **Wet AMD Program**: RGX-314 is positioned as a potential first non-rare gene therapy approved, with significant commercial readiness efforts in collaboration with AbbVie [9][25]. Manufacturing and Scalability - **Manufacturing Capabilities**: The company has advanced manufacturing processes, capable of producing 2,500 doses per year for RGX-202 and up to 350,000 doses for RGX-314 [28][29]. - **Quality Control**: Achieved an 80% full capsid level in batches, which is critical for safety and efficacy [29]. Safety and Efficacy - **Immune Suppression Regimen**: A proactive immune suppression strategy has been implemented to enhance safety and efficacy, allowing for higher dosing without significant adverse effects [36][37]. - **Clinical Outcomes**: Positive safety profiles and functional benefits observed in patients, with significant improvements in NSAA scores [19][17]. Additional Important Content - **Global Expansion**: Plans for expanding clinical studies outside the U.S. to address broader patient needs [21][39]. - **Partnerships**: Collaboration with AbbVie for the wet AMD program, leveraging their existing sales force and expertise in ophthalmology [43][44]. - **Market Potential**: The company is targeting significant unmet needs in rare diseases and chronic retinal diseases, with a focus on long-term patient outcomes and reducing treatment burdens [31][27]. Conclusion - **Future Outlook**: Regenxbio is positioned for a transformative year with multiple late-stage catalysts, a strong manufacturing base, and a commitment to patient-centric outcomes in gene therapy [31].

Core Insights - REGENXBIO Inc. is poised for a transformative year in 2026, entering the commercial stage with two near-term catalysts from its late-stage assets and a clear path to sustained growth [2] - The company has reported positive long-term data for its Duchenne program, indicating effective therapeutic benefits across its gene therapy pipeline [2] Clinical Program Updates and 2026 Anticipated Milestones - New functional data from the Phase I/II AFFINITY DUCHENNE trial for RGX-202 shows that all four patients exceeded expected disease trajectory, improving an average of 7.4 points on the North Star Ambulatory Assessment (NSAA) [3] - The company plans to present additional safety, biomarker, and functional data at the MDA Clinical and Scientific Conference in March 2026 [3] - REGENXBIO expects to submit a Biologics License Application (BLA) under the accelerated approval pathway in mid-2026, following the completion of enrollment in the pivotal trial [7] Regulatory and Commercial Readiness - The FDA PDUFA target date for the Duchenne program is February 8, 2026, with potential approval leading to a Priority Review Voucher (PRV) [7] - REGENXBIO is collaborating with Nippon Shinyaku for the commercialization of clemidsogene lanparvovec (RGX-121) upon potential approval [7] - The company is enhancing its manufacturing capabilities at its Manufacturing Innovation Center in Rockville, Maryland, to support commercial launches [8] Gene Therapy Advancements - REGENXBIO is advancing its AAV gene delivery technology through capsid discovery and engineering, approaching IND readiness for treating geographic atrophy [9] - The company is on track to make surabgene lomparvovec (sura-vec) the first gene therapy for wet age-related macular degeneration (AMD) [12] - A two-part Phase IIb/III trial for sura-vec in diabetic retinopathy is set to begin, with a $100 million milestone payment from AbbVie expected upon the first patient dosing [12]

Core Viewpoint - REGENXBIO Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its advancements in gene therapy and its late-stage pipeline of treatments for rare and retinal diseases [1][2]. Company Overview - REGENXBIO is a biotechnology company founded in 2009, focused on gene therapy with a pioneering role in AAV gene therapy [3]. - The company is advancing a late-stage pipeline that includes treatments for Duchenne (RGX-202), MPS II (clemidsogene lanparvovec, RGX-121), and MPS I (RGX-111), in partnership with Nippon Shinyaku [3]. - Additionally, REGENXBIO is collaborating with AbbVie on surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy [3]. - Thousands of patients have been treated using REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® [3]. - The investigational gene therapies from REGENXBIO have the potential to significantly impact healthcare delivery for millions [3].

Summary of Capricor Therapeutics FY Conference Call Company Overview - **Company**: Capricor Therapeutics (NasdaqCM: CAPR) - **Focus**: Development of deramiocel for treating cardiomyopathy caused by Duchenne muscular dystrophy (DMD) [1][2] Key Points and Arguments Clinical Data and Efficacy - **HOPE-3 Trial**: Positive results reported from a randomized double-blind placebo-controlled trial involving 106 patients, with 105 completing the study [4][5] - **Primary Endpoint**: Achieved statistical significance with a p-value of 0.03 for the Performance of the Upper Limb 2.0, indicating a clinically relevant 1.2-point change [5][6] - **Secondary Endpoint**: Left ventricular ejection fraction also showed statistical significance with a p-value of 0.04, indicating potential for treating heart disease in DMD patients [6][7] - **Patient Response**: 40% of patients showed improvement in both cardiac and skeletal muscle function, while over 70% had improvement in either [14] Regulatory and Approval Process - **Complete Response Letter (CRL)**: The FDA previously issued a CRL citing insufficient data from earlier studies; however, the new HOPE-3 data is expected to address these concerns [10][11] - **Resubmission Timeline**: Capricor plans to respond to the CRL by the end of the calendar year, anticipating a PDUFA date around July of the following year [11][12] Market Opportunity - **Partnership with Nippon Shinyaku**: Capricor has a sales and distribution agreement, which includes an $80 million milestone payment upon approval and royalties between 30%-50% [16][17] - **Target Population**: DMD affects approximately 15,000 to 20,000 boys and young men in the U.S., presenting a significant market opportunity [17] - **Pricing Strategy**: Capricor aims to price deramiocel competitively within the range of existing exon-skipping therapies, which could lead to a robust revenue model [17] Manufacturing and Expansion Plans - **Manufacturing Facility**: A new commercial-scale facility in San Diego is ready to meet initial demand for about 500 patients, with plans to expand capacity for 2,500 patients annually [21][25] - **Potential for Exosome Development**: Capricor is exploring the use of exosomes for advanced genetic medicine, leveraging their manufacturing capabilities to scale up production [33][34] Future Indications - **Expansion into Becker's Muscular Dystrophy**: Plans to seek accelerated approval for Becker's, which shares similar cardiomyopathy characteristics with DMD, are in development [27][28] - **Broader Neuromuscular Disease Applications**: Capricor is considering expanding deramiocel's application to other neuromuscular diseases with cardiac components [29] Additional Important Information - **Financial Position**: Capricor ended the third quarter with nearly $100 million in cash, with potential additional funding from milestone payments and sales [31] - **Clean Capital Structure**: The company has no debt, positioning it well for future growth and development [31] This summary encapsulates the critical insights from the conference call, highlighting Capricor Therapeutics' advancements, market potential, and strategic plans for the future.

Core Insights - REGENXBIO Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference with a fireside chat scheduled for December 2, 2025, at 8:30 a.m. ET [1] - The company is focused on advancing gene therapy, particularly in treating rare and retinal diseases, with a late-stage pipeline that includes several investigational therapies [2] Company Overview - REGENXBIO, founded in 2009, specializes in AAV gene therapy and aims to improve lives through its curative potential [2] - The company has developed treatments such as RGX-202 for Duchenne muscular dystrophy, RGX-121 for MPS II, and RGX-111 for MPS I, in collaboration with Nippon Shinyaku [2] - REGENXBIO is also working with AbbVie on surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy [2] - Thousands of patients have been treated using REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® [2] Recent Developments - The company announced the completion of pivotal enrollment in the AFFINITY DUCHENNE® trial for RGX-202, marking a significant milestone in its Duchenne gene therapy program [5]

Financial Data and Key Metrics Changes - REGENXBIO ended Q3 2025 with cash, cash equivalents, and marketable securities of $302 million, an increase from $245 million as of December 31, 2024, primarily driven by a $110 million upfront payment from Nippon Shinyaku and $145 million in net proceeds from royalty monetization [17][18] - Revenues for Q3 2025 were $30 million, compared to $24 million in Q3 2024, mainly due to development service revenue under the Nippon Shinyaku partnership [17] Business Line Data and Key Metrics Changes - The RGX-202 program for Duchenne muscular dystrophy is progressing well, with enrollment completed in the Affinity Duchenne Pivotal Trial, and top-line pivotal data expected in early Q2 2026 [5][11] - RGX-121, a potential gene therapy for MPS II, is on track for FDA approval by early 2026, with positive 12-month data delivered to the FDA [8][14] - The retinal disease franchise, particularly the ABBV-RGX-314 program for wet AMD, has completed enrollment in two global phase 3 studies, representing the largest global gene therapy program ever conducted [9][10] Market Data and Key Metrics Changes - The anticipated market for RGX-202 is significant, with the ability to produce 2,500 doses per year, positioning the company for clinical and commercial success [7] - The prevalent market for Duchenne is expected to be around 14,000 patients by 2027, with approximately 3,000 eligible for gene therapy [82] Company Strategy and Development Direction - The company is focused on advancing its late-stage pipeline of gene therapies, with a commitment to bringing new medicines to patients in need [4] - REGENXBIO is preparing for a commercial launch of RGX-202 in 2027 and is exploring opportunities to expand the program outside the U.S. [6][14] - The company aims to leverage its manufacturing capabilities and innovative science to deliver best-in-class therapeutics [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing BLA review for RGX-121, highlighting productive interactions with the FDA and a strong safety profile [8][32] - The company anticipates a transformational year ahead, with multiple product launches and significant unmet needs being addressed by its gene therapies [19] Other Important Information - The company has a strong financial position, with cash runway expected to extend into early 2027, not including potential non-dilutive financing opportunities [18] - The manufacturing facility in Rockville is capable of producing high-purity gene therapies, which is crucial for commercial readiness [7][35] Q&A Session Summary Question: Update on RGX-202 interactions with FDA - Management indicated that top-line data will be available in early Q2 2026, with a pre-BLA meeting expected around that time [21][23] Question: Cash runway and non-dilutive financing - The company expects non-dilutive financing options to extend cash runway well into 2027 or early 2028 [24][25] Question: Confirmatory trial enrollment for DMD - Enrollment for the confirmatory study has begun, and management expects substantial progress by mid-2026 [26][27] Question: Regulatory interactions for DMD and MPS II - Management confirmed a late cycle meeting with the FDA for RGX-121 and a pre-BLA meeting for RGX-202 is anticipated [30][32] Question: Manufacturing capacity and production volume - The Rockville site has a 2,000-liter bioreactor, capable of producing up to 2,500 doses of RGX-202 annually [34][35] Question: Use of FDA natural history as a control in DMD - Management confirmed that propensity score matching is prospectively specified in the protocol for RGX-202 [38][40] Question: Interest in gene therapy from retina specialists - There is significant excitement about gene therapy among retina specialists, with half of surveyed specialists expressing interest in gene therapy approaches [42][44] Question: Expectations for black box warnings - Management does not expect a black box warning for RGX-202 due to its strong safety profile [48][49] Question: EMA plans and requirements - The company is evaluating the EMA's requirements for RGX-121 and RGX-202, with ongoing discussions about potential placebo control needs [52][54] Question: Diabetic retinopathy study adjustments - The company is considering the ordinal two-step DRSS change as a potential primary endpoint for their pivotal studies [58][61] Question: Enrollment for suprachoroidal delivery program - The company is looking to enroll 20 patients in the suprachoroidal delivery arm, with expectations for increased enrollment speed following the completion of the subretinal program [63][66]

Core Insights - REGENXBIO Inc. reported significant progress in its late-stage gene therapy programs, highlighting advancements in treatments for Duchenne muscular dystrophy, Hunter syndrome, wet AMD, and diabetic retinopathy [2][3]. Financial Performance - Cash, cash equivalents, and marketable securities totaled $302.0 million as of September 30, 2025, an increase from $244.9 million at the end of 2024, primarily due to a $110.0 million upfront payment from Nippon Shinyaku and $144.5 million from royalty monetization [7]. - Revenues for Q3 2025 were $29.7 million, up from $24.2 million in Q3 2024, driven by $5.9 million in development service revenue from the Nippon Shinyaku partnership [8]. - Research and development expenses rose to $56.1 million in Q3 2025 from $54.4 million in Q3 2024, mainly due to increased personnel and manufacturing costs [9]. - General and administrative expenses increased to $20.3 million in Q3 2025 from $19.4 million in Q3 2024, attributed to professional services and consulting [10]. - The net loss for Q3 2025 was $61.9 million, compared to a net loss of $59.6 million in Q3 2024, resulting in a basic and diluted net loss per share of $1.20 [11]. Program Highlights - RGX-202, a gene therapy for Duchenne muscular dystrophy, is advancing rapidly with topline results expected in early Q2 2026 and a Biologics License Application (BLA) submission planned for mid-2026 [5][6]. - Clemidsogene lanparvovec (RGX-121) is on track to be the first gene therapy for Hunter syndrome, with a PDUFA date set for February 8, 2026 [4][12]. - Surabgene lomparvovec (sura-vec) is positioned to be the first gene therapy for chronic retinal diseases, with pivotal trial enrollment completed and topline data expected in Q4 2026 [5][7]. Operational Developments - Enrollment in the pivotal trial for RGX-202 was completed in October 2025, with ongoing confirmatory studies for ambulatory patients [6]. - REGENXBIO has begun manufacturing RGX-202 for commercial supply, anticipating a launch in 2027 [6]. - The company presented positive 12-month data for RGX-121, showing significant biomarker reductions and correlations with neurodevelopmental outcomes [12]. Future Outlook - REGENXBIO expects its cash position to fund operations into early 2027, excluding potential milestone payments from partners [13]. - The company is preparing for a conference call to discuss these results and operational highlights [14].

Core Insights - REGENXBIO Inc. announced the presentation of interim data from the Phase II ALTITUDE trial for surabgene lomparvovec (ABBV-RGX-314) targeting diabetic retinopathy at the American Academy of Ophthalmology 2025 Annual Meeting [1][2] - Surabgene lomparvovec is a one-time gene therapy developed in collaboration with AbbVie, aimed at treating wet age-related macular degeneration and diabetic retinopathy [1][2] Company Overview - REGENXBIO is a biotechnology company focused on gene therapy, founded in 2009, and has developed a late-stage pipeline for various diseases, including RGX-202 for Duchenne and RGX-121 for MPS II [3] - The company utilizes the NAV AAV8 vector in surabgene lomparvovec, which encodes an antibody fragment to inhibit vascular endothelial growth factor (VEGF), a key factor in the development of leaky blood vessels in the retina [2][3]